share_log

国药现代(600420.SH)：阿莫西林克拉维酸钾片通过仿制药一致性评价

Shanghai Shyndec Pharmaceutical (600420.SH): Amoxicillin Clavulanic Acid Potassium Tablets pass generic consistency evaluation.

Gelonghui Finance ·  Jul 15 04:59

On July 15th, Gelunhui reported that Shanghai Shyndec Pharmaceutical (600420.SH), a wholly-owned subsidiary of China National Pharmaceutical Group, received the "Drug Supplementary Application Approval Notice" issued by the State Drug Administration Approval; Amoxicillin Clavulanate Potassium Tablets were approved through the generic drug quality and efficacy consistency evaluation. The active ingredients of amoxicillin clavulanate potassium tablets are amoxicillin and clavulanic acid. Amoxicillin is a broad-spectrum penicillin antibiotic, and clavulanic acid potassium itself has only weak antibacterial activity, but has a powerful broad-spectrum beta-lactamase inhibition. When used together, it can protect amoxicillin from beta-lactamase hydrolysis. The antibacterial spectrum of this product is the same as that of amoxicillin, and it has been expanded. It has a good effect on methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, coagulase-negative Staphylococcus and Enterococcus, and also has good antibacterial activity against some beta-lactamase-producing Enterobacteriaceae bacteria, influenza bacillus, K. pneumoniae, and fragile pseudomonas.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment